Advertisement


Nancy Davidson: Serendipity and Purpose (with Allen S. Lichter, MD)

2018 ASCO Annual Meeting

Advertisement

Allen S. Lichter, MD, ASCO’s former Chief Executive Officer, talks with Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, the 2018 recipient of the Visionary Leader Award, named for Dr. Lichter.



Related Videos

Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, and Lisa A. Carey, MD, on Breast Cancer: Commentary on the TAILORx Trial

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center, and Lisa A. Carey, MD, of the University of North Carolina, discuss the impact of new phase III findings on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer (Abstract LBA1).

Breast Cancer

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Results From the PAKT Trial

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (Abstract 1007).

Leukemia

William G. Wierda, MD, PhD, and Julie M. Vose, MD, MBA, on CLL: Results From the CAPTIVATE Trial

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss phase II findings on ibrutinib plus venetoclax in first-line treatment of chronic lymphocytic leukemia (Abstract 7502).

Lung Cancer

Naoki Furuya, MD, PhD, on NSCLC: Results From the NEJ026 Study

Naoki Furuya, MD, PhD, of the St. Marianna University School of Medicine, discusses phase III study findings on a comparison of bevacizumab plus erlotinib to erlotinib in patients with untreated non–small cell lung cancer with activating EGFR mutations (Abstract 9006).

Gynecologic Cancers
Immunotherapy

Ursula A. Matulonis, MD, and Stéphanie Gaillard, MD, PhD, on Ovarian Cancer: Results From an NRG Oncology/COG Trial

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Stéphanie Gaillard, MD, PhD, of Duke Cancer Institute, discuss an evaluation of bevacizumab in the primary treatment of advanced ovarian cancer (Abstract 5517).

Advertisement

Advertisement




Advertisement